Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04625322
Other study ID # 20-5188
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date April 19, 2022
Est. completion date April 2023

Study information

Verified date December 2021
Source University Health Network, Toronto
Contact Mia Biondi, NP-PHC, PhD
Phone 6476286461
Email mia.biondi@mail.mcgill.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hepatitis C virus (HCV) disproportionally affects certain populations, including those facing substance use and mental health challenges. In the past, many individuals with mental illness were not treated due to the psychiatric side-effects of interferon. However, the development of highly effective, direct-acting antivirals (DAA) has revolutionized HCV treatment such that cure rates are >95% with 8-12 weeks of simple, safe, and well-tolerated therapy. A recent systematic review reported that across 13 North American studies, HCV prevalence among people admitted to psychiatric hospitals was a staggering 17.4% (13.2-22.6%). Despite these concerning figures, mental health facilities have not been a focus of HCV elimination efforts to date. The Centre for Addiction and Mental Health (CAMH) in Toronto is the largest mental health facility in Canada, with a psychiatric emergency department seeing ~35 patients per day with many admitted to the acute psychiatric units for safety and stabilization. Currently, psychiatric patients screened for HCV at CAMH have a 75% 'no show' rate at the Toronto Centre for Liver Disease (TCLD), which is located less than 5km away, suggesting that referral upon discharge is ineffective. This study will be the first trial to evaluate whether it would be feasible and beneficial to initiate treatment during an acute psychiatric admission rather than referring to specialty upon discharge. The combination of broad HCV screening with rapid linkage to treatment has led to successful elimination of HCV within defined populations, so-called micro-elimination. The investigators hypothesize that HCV treatment can be effectively delivered by providers in psychiatric care facilities, which will improve treatment uptake over traditional referral models.


Recruitment information / eligibility

Status Recruiting
Enrollment 54
Est. completion date April 2023
Est. primary completion date April 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Chronic HCV infection, positive HCV RNA 2. Aged 18 to 80 3. Willingness and capacity to provide informed consent, or consent is provided by a substitute decision maker Exclusion Criteria: 1. Presence of or history of decompensated cirrhosis (evidence of decompensation with history of either ascites, variceal hemorrhage, or hepatic encephalopathy) 2. Platelets < 75,000/mm3, total albumin <35 g/L, total bilirubin >34 µmol/L, INR >1.5 3. History of current or past hepatocellular carcinoma. 4. HBV (HBsAg +ve) co-infection or untreated HIV co-infection 5. Prior HCV antiviral therapy with DAA with or without peginterferon/ribavirin 6. Chronic liver disease other than mild nonalcoholic or alcoholic fatty liver disease from a cause other than HCV 7. Pregnancy/breastfeeding/inability to use contraception 8. Use of concomitant contraindicated medications

Study Design


Related Conditions & MeSH terms


Intervention

Other:
HCV care provided by hospitalist during acute psychiatric admission
HCV diagnosis and treatment will be conducted by a hospitalist during an acute psychiatric admission at CAMH

Locations

Country Name City State
Canada Centre for Addiction and Mental Health Toronto Ontario

Sponsors (2)

Lead Sponsor Collaborator
University Health Network, Toronto Centre for Addiction and Mental Health

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary SVR12 by intention to treat (ITT) in each arm To determine whether screening for HCV using rapid diagnostics during an acute psychiatric admission with inpatient initiation of HCV treatment is superior to standard post-discharge referral and treatment by intention to treat (ITT). 24 months
Secondary SVR12 by modified intention to treat (mITT) in each arm To determine whether screening for HCV using rapid diagnostics during an acute psychiatric admission with inpatient initiation of HCV treatment is superior to standard post-discharge referral and treatment by modified intention to treat (mITT). 24 months
Secondary HCV relapse rate To compare the HCV viral relapse rate in both arms (re-appearance of HCV RNA in those undetectable at end of treatment; relapse distinguished from reinfection by sequencing of the recurrent HCV RNA and comparing to baseline). 24 months
Secondary HCV seroprevalence rates To determine HCV seroprevalence rates among acute vs addictions patients admitted to CAMH. 12 months
Secondary HCV RNA positivity rates To determine HCV RNA positivity rates among acute vs addictions patients admitted to CAMH. 12 months
Secondary CAMH staff acceptability of POC antibody and RNA testing CAMH staff involved in the trial will be asked to particiapte in an acceptibility survey regarding rapid POC antibody and RNA testing on the acute units. 12 months
Secondary Concordance of POC HCV RNA with HCV RNA by phlebotomy To determine concordance of POC HCV RNA (GeneXpert) with HCV RNA by phlebotomy (Abbott RealTime). 12 months
Secondary Minimum and mean times from diagnosis to treatment initiation Evaluate the mean and minimum times to treatment initiation in both arms, and compare. 24 months
Secondary Adherence with out-patient follow-up visits Evaluate and compare out-patient follow-up visit adherence in both arms. 24 months.
Secondary Adherence to HCV treatment, by HCV regimen Evaluate and compare both arms for medication adherence (patient self-report and pill count), and variance by medication regimen. 24 months.
Secondary Adverse events while on HCV treatment To determine and compare adverse events in both arms while patients are on treatment. 18 months.
Secondary HCV Reinfection Reinfection rates by the end of the defined as HCV RNA detectability after prior SVR with demonstration of distinct viral sequence from baseline sample to distinguish 24 months.
See also
  Status Clinical Trial Phase
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Recruiting NCT04510246 - Link Hepatitis C Notifications to Treatment in Tasmania N/A
Completed NCT03413696 - Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
Completed NCT03118674 - Harvoni Treatment Porphyria Cutanea Tarda Phase 2
Completed NCT03109457 - Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma
Completed NCT01458054 - Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults Phase 1
Completed NCT03740230 - An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs
Completed NCT03426787 - Helping Empower Liver and Kidney Patients N/A
Completed NCT03627299 - Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors Phase 4
Completed NCT00006301 - Immune Response to Hepatitis C Virus
Active, not recruiting NCT03949764 - The Kentucky Viral Hepatitis Treatment Study Phase 4
Completed NCT03365635 - Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C Phase 4
Recruiting NCT04405024 - Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients N/A
Completed NCT04525690 - Improving Inpatient Screening for Hepatitis C N/A
Completed NCT04033887 - Evaluation Study of RDTs Detecting Antibodies Against HCV
Withdrawn NCT04546802 - HepATocellular Cancer Hcv Therapy Study Phase 3
Active, not recruiting NCT02961426 - Strategic Transformation of the Market of HCV Treatments Phase 2/Phase 3
Completed NCT02705534 - Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1 Phase 3
Completed NCT03186313 - A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection Phase 3
Completed NCT02683005 - Study of Hepatitis C Treatment During Pregnancy Phase 1